First in Human Study of NVG-111 in Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is the first clinical trial of the drug NVG-111, and will include patients with certain
types of blood cancer called chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma
(SLL) and mantle cell lymphoma (MCL). NVG-111 is a bispecific antibody drug, having two
"arms", one arm attaches to a substance on cancer cells called ROR1, the other arm attaches
to the body's immune cells directing them to kill the cancer cells.
The trial has two parts, the first part tests the safety of the drug at different dose
levels. Once the first part of the study is complete a dose will be chosen for the second
part of the study. The second part of the study will test how well NVG-111 works in treating
these diseases.